Business
Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesC
About this update from Nkarta, Inc.
[{"type":"image","alt":"Nkarta, Inc.","displaySize":"","headline":null,"caption":"Nkarta, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":78,"url":"https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/E3HnIhM4alJb8N_ScZ3_Cw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/b219d2cd4667e3c48fb6f35de22e2af0","width":300,"height":78}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseases","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025","length":90,"tagName":"p"}]},{"val":[{"type":"text","content":"Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestones","length":252,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance of $380.5 million on December 31, 2024, including cash, cash equivalents and investments, expected to fund operations into 2029","length":140,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":639,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024.","length":283,"tagName":"p"},{"type":"text","content":"“As the validation of cellular therapy in autoimmune disease expands to include CAR NK cells, we remain confident that the potential safety and accessibility advantages of NKX019 will allow it to occupy an important place in the future treatment of autoimmune disease,” said Paul J. Hastings, CEO of Nkarta. “The opportunity that novel B-cell targeting therapies like NKX019 have to become transformative is substantial, creating a highly competitive development landscape. The integration of cellular therapy into traditional...